Document Detail

Verapamil induced ventricular hypertrophy in conscious dogs.
MedLine Citation:
PMID:  2532064     Owner:  NLM     Status:  MEDLINE    
Verapamil is used clinically in the treatment of various cardiac diseases including hypertrophic cardiomyopathy. Its long term effects on ventricular mass are not well known. In 11 conscious dogs heart rate, aortic and left ventricular pressures, cardiac output, a methoxamine induced stress ventricular function test and left ventriculography were performed. These variables were measured prior to and following a mean 7.2 month infusion of verapamil at 0.005 or 0.01 using a subcutaneously implanted pump. Resting haemodynamic variables and left ventricular ejection fraction [60(SD 6) v 55(6)%] were unchanged between baseline and chronic verapamil studies, but the slope of the methoxamine induced stress ventricular function test decreased from 3.9(0.8) to 2.1 (1.3). After verapamil was discontinued the mean slope of the stress ventricular function test returned to the baseline 4.0(1.7). Total ventricular weight increased 22% from 176.1(17.5) g.m-2 in controls to 215.6(29.5) g.m-2 (p less than 0.01) in the verapamil animals. The right ventricular weight increased 25% from 46(5.9) to 57.6(9.1) g.m-2 (p less than 0.01); the septum weight increased 26% from 42.5(4.1) to 53.7(7.2) g.m-2 (p less than 0.001); and the left ventricular free wall weight increased 19% from 87.4(9.8) to 103.9(15.7) g.m-2 (p less than 0.01). The increase in ventricular weights was not due to fibrosis or oedema since hydroxyproline contents and wet/dry ratios were not increased. In conclusion, a chronic infusion of verapamil in conscious dogs caused no change in resting haemodynamic variables but produced reversible depression of stress ventricular function and biventricular and septal hypertrophy.
W J French; D Garner; G E Adomian; W Averill; M M Laks
Related Documents :
10756124 - Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition.
128424 - Noninvasive evaluation of ventricular hypertrophy in professional athletes.
144034 - Cardiac size and function in acromegaly.
14654734 - Extracellular matrix biology: a new frontier in linking the pathology and therapy of hy...
7574954 - Normothermic versus mild hypothermic retrograde blood cardioplegia: a prospective, rand...
10878704 - Stress echocardiography for the diagnosis of ischaemia in hypertensives.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cardiovascular research     Volume:  23     ISSN:  0008-6363     ISO Abbreviation:  Cardiovasc. Res.     Publication Date:  1989 Aug 
Date Detail:
Created Date:  1990-02-06     Completed Date:  1990-02-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0077427     Medline TA:  Cardiovasc Res     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  695-701     Citation Subset:  IM    
Department of Medicine, UCLA School of Medicine.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiomegaly / chemically induced*
Heart / drug effects
Hemodynamics / drug effects
Infusion Pumps, Implantable
Methoxamine / diagnostic use
Myocardium / pathology
Organ Size / drug effects
Verapamil / administration & dosage,  toxicity*
Grant Support
Reg. No./Substance:
390-28-3/Methoxamine; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Noradrenaline, atrial natriuretic peptide, bombesin and neurotensin in myocardium and blood of rats ...
Next Document:  Uneven host tissue ongrowth and tissue detachment in stent mounted heart valve allografts and xenogr...